“Bupropion and Naltrexone in Methamphetamine Use Disorder”, N Engl J Med, vol. 384, no. 2, pp. 140-153, 2021.
, “Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.”, Lancet, vol. 391, no. 10118, pp. 309-318, 2018.
, “Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.”, Contemp Clin Trials, vol. 33, no. 2, pp. 386-95, 2012.
, “Internet-delivered treatment for substance abuse: a multisite randomized controlled trial.”, Am J Psychiatry, vol. 171, no. 6, pp. 683-90, 2014.
, “NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.”, Contemp Clin Trials, vol. 50, pp. 253-64, 2016.
, “Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study”, Contemp Clin Trials, vol. 128, p. 107148, 2023.
, “Web-based, psychosocial treatment for substance use disorders in community treatment settings.”, Psychol Serv, vol. 9, no. 2, pp. 212-4, 2012.
,